This research identifies small cell lung cancer (SCLC) as a "cold" tumor that evades the immune system by suppressing MHC-I expression and creating an inactive vascular barrier. While certain neuroendocrine cancer cells are highly vulnerable to Natural Killer (NK) cells, they remain protected because the tumor blood vessels fail to recruit these immune effectors. By utilizing a specialized 3D microphysiological model called DynaMITE-seq, researchers discovered that activating the STING signaling pathway within the tumor vasculature can restart immune cell trafficking. This vascular activation triggers the production of chemokines and adhesion molecules, effectively opening the "gates" for immune infiltration. The study demonstrates that combining STING agonists with engineered DLL3 CAR-NK cells significantly enhances tumor destruction. These findings offer a strategic roadmap for warming up cold tumors to improve the efficacy of adoptive cell therapies in solid malignancies.

References:

• Campisi M, Osaki T, Dryg I, et al. Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer[J]. Cancer Cell, 2026.